Platinum Investment Management’s ADC Therapeutics ADCT Stock Holding History

Platinum Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$622K	Sell	581,609 -409,169	-41%	-$1.19M	0.15%	81
2026 Q1	$3.72M	Hold	990,778	–	–	0.94%	40
2025 Q4	$3.5M	Sell	990,778 -165,943	-14%	-$673K	0.81%	50
2025 Q3	$4.63M	Sell	1,156,721 -230,544	-17%	-$727K	0.3%	39
2025 Q2	$3.72M	Sell	1,387,265 -650,822	-32%	-$1.37M	0.25%	42
2025 Q1	$2.87M	Buy	2,038,087 +425,531	+26%	+$723K	0.17%	41
2024 Q4	$3.21M	Buy	1,612,556 +168,040	+12%	+$440K	0.19%	49
2024 Q3	$4.55M	Buy	1,444,516 +148,363	+11%	+$468K	0.21%	41
2024 Q2	$4.1M	Buy	+1,296,153	New	+$5.15M	0.17%	43

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Platinum Investment Management's ADCT Position: Q2 2026 in Review

Platinum Investment Management reduced its ADC Therapeutics (ADCT) stake by 41% in Q2 2026, selling an estimated $1.19M and leaving 581,609 shares worth $622K. The position accounts for 0.15% of the portfolio, ranked #81.

Platinum Investment Management first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.63M in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Platinum Investment Management held 581,609 shares of ADC Therapeutics worth $622K as of Q2 2026.
Platinum Investment Management sold 409,169 ADC Therapeutics shares in Q2 2026, an estimated $1.19M.
ADC Therapeutics made up 0.15% of Platinum Investment Management's portfolio in Q2 2026, its #81 holding.
Platinum Investment Management first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
Platinum Investment Management's ADC Therapeutics position peaked at $4.63M in Q3 2025.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Platinum Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.